Overview

Arsenal Biosciences focuses on developing programmable cell therapies to treat solid tumor cancers. Their approach involves reprogramming cells to enhance their ability to fight cancer. The company is currently in the clinical stage, concentrating on research and development to bring these therapies to market. Their target clients are patients with solid tumor cancers, a significant segment of the cancer patient population. Arsenal generates revenue through the commercialization of these therapies once they receive approval. The team consists of experts from various scientific fields and professionals with clinical and manufacturing backgrounds, all working together to create effective cancer treatments.

Simplify's Take

What believers are saying

• Recent $325 million funding boosts ArsenalBio's clinical development capabilities.
• Partnerships with Thermo Fisher enhance ArsenalBio's manufacturing and technological capabilities.
• Growing demand for personalized medicine aligns with ArsenalBio's programmable cell therapy focus.

What critics are saying

• Emerging competition from companies like Allogene Therapeutics in CAR T-cell therapies.
• High manufacturing costs may affect ArsenalBio's pricing and market competitiveness.
• Regulatory scrutiny on gene-editing technologies could delay therapy approvals.

What makes ArsenalBio unique

• ArsenalBio integrates CRISPR, synthetic biology, and machine learning for advanced cell therapies.
• Their focus on solid tumors sets them apart in the CAR T-cell therapy space.
• ArsenalBio's CITE technology enhances T-cell targeting and tumor microenvironment overcoming.

Help us improve and share your feedback! Did you find this helpful?

YesNo

Funding

Total Funding

$630M

Above

Industry Average

Funded Over

3 Rounds

Notable Investors:

Kleiner PerkinsSoftBank

Notable Investors:

Kleiner PerkinsSoftBank

$325,000,000

Series C

Sep 2024

Series C funding is usually for startups that are doing well and are looking for more money to fuel major growth, such as acquiring other companies, expanding into global markets, or launching new product lines. Investors typically include larger venture capital firms and private equity.

Series C Funding Comparison

Above Average

Industry standards

Ind Avg. $50M

$16M

$40M

$50M

$62M

$100M

$325M

View all funding stages